Top
News Updates

Gopal Subramanium, First Indian Senior Counsel To Appear Before The Singapore Supreme Court, Wins Appeal In the Daiichi - Ranbaxy Matter

Akshita Saxena
29 May 2020 9:52 AM GMT
Gopal Subramanium, First Indian Senior Counsel To Appear Before The Singapore Supreme Court, Wins Appeal In the Daiichi - Ranbaxy Matter
Your free access to Live Law has expired
To read the article, get a premium account.
    Your Subscription Supports Independent Journalism
Subscription starts from
599+GST
(For 6 Months)
Premium account gives you:
  • Unlimited access to Live Law Archives, Weekly/Monthly Digest, Exclusive Notifications, Comments.
  • Reading experience of Ad Free Version, Petition Copies, Judgement/Order Copies.
Already a subscriber?

In a huge setback to former promoters of Ranbaxy -- Malvinder Mohan Singh and Shivinder Mohan Singh, the Supreme Court of Singapore on Thursday dismissed their appeal against the judgment of the High Court of Singapore refusing to set aside the Rs 3,500-crore arbitral award in favour of Japanese drug maker Daiichi Sankyo.

With this, Senior Advocate Gopal Subramanium, representing Daiichi Sankyo, has become the first Indian to appear before the Singapore Supreme Court (Court of Appeal).

Background

On April 29, 2016, the Arbitral Tribunal comprising Professor Lawrence GS Boo, Karyll Nairn and Justice (Retd.) AM Ahmadi had held that the Sellers (the Singh brothers) are jointly and severally liable to pay damages for the harm suffered by the Buyer (Daiichi) as a result of the fraudulent concealment of a Self-Assessment Report concerning a pending investigations by the US Food and Drug Administration and Department of Justice.

Pursuant to this, Daiichi approached the Delhi High Court seeking enforcement of the award. Thereby, Justice Jayant Nath held that the award was enforceable, except against five minors, including Singh's children, as "Article 15, 39(e) and (f) and 45 of the Constitution of India empower the state to make special provisions for protection of children".

This order came to be challenged by Singh brothers before the Indian Supreme Court. However, the Bench comprising Justice Gogoi and Justice Banumathi dismissed the SLP saying that they are "not inclined to interfere" with the impugned judgment.

The arbitral award was also a subject matter of challenge before the High Court of Singapore which, in its verdict dated December 21, 2018 upheld the award of the Singapore seated ICC arbitral tribunal in favour of Daiichi Sankyo.

This order of the High Court of Singapore was upheld by the country's Supreme Court yesterday.

Daiichi Sankyo was represented by senior counsel Gopal Subramanium. Mr Subramanium was briefed by P&A Law Offices (Anand Pathak / Amit Mishra / Mohit Singh / Samridhi Hota / Kanika Singhal / Shivam Pandey / Turab Ali Kazmi) and assisted by Pavan Bhushan, Hima Lawrence, Jayavardhan Singh from Mr Subramanium's Chambers along with Singapore-based law firm, Oon & Bazul LLP.

Mr Subramanium was the first Indian Senior Counsel to have appeared before the Singapore Supreme Court.

Malvinder Mohan Singh was represented by Yeo Khirn Hai Alvin SC, briefed by WongPartnership LLP and DMD Advocates; and Shivinder Mohan Singh was represented by Narayanan Sreenivasan SC, briefed by K&L Gates Straits Law LLC.

Pertinently, Singh brothers have also been held guilty of contempt by the Supreme Court of India for violating its order asking them not to divest their shares in Fortis Healthcare Limited. The Top Court had asked also Singh brothers to give it a plan as to how they would honour the arbitral award of Rs 3,500 crore granted by a Singapore tribunal against them and in favour of Japanese drug manufacturer Daiichi Sankyo.

Nevertheless, they effected sale of their controlling stakes in Fortis Group to Malayasian firm IHH Healthcare.


Next Story